175 related articles for article (PubMed ID: 17579344)
1. PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL.
Caravatta L; Sancilio S; di Giacomo V; Rana R; Cataldi A; Di Pietro R
J Cell Physiol; 2008 Jan; 214(1):192-200. PubMed ID: 17579344
[TBL] [Abstract][Full Text] [Related]
2. PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment.
Zauli G; Sancilio S; Cataldi A; Sabatini N; Bosco D; Di Pietro R
J Cell Physiol; 2005 Mar; 202(3):900-11. PubMed ID: 15389633
[TBL] [Abstract][Full Text] [Related]
3. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.
Uddin S; Hussain AR; Al-Hussein KA; Manogaran PS; Wickrema A; Gutierrez MI; Bhatia KG
Clin Cancer Res; 2005 Apr; 11(8):3102-8. PubMed ID: 15837766
[TBL] [Abstract][Full Text] [Related]
5. Differential response of neuroblastoma cells to TRAIL is independent of PI3K/AKT.
Efron PA; Chen MK; Iyengar M; Dai W; Nagaram A; Beierle EA
J Pediatr Surg; 2006 Jun; 41(6):1072-80. PubMed ID: 16769337
[TBL] [Abstract][Full Text] [Related]
6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
7. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis.
Joy AM; Beaudry CE; Tran NL; Ponce FA; Holz DR; Demuth T; Berens ME
J Cell Sci; 2003 Nov; 116(Pt 21):4409-17. PubMed ID: 13130092
[TBL] [Abstract][Full Text] [Related]
8. PI-3-kinase/NF-kappaB mediated response of Jurkat T leukemic cells to two different chemotherapeutic drugs, etoposide and TRAIL.
Sabatini N; Di Pietro R; Rapino M; Sancilio S; Comani S; Cataldi A
J Cell Biochem; 2004 Oct; 93(2):301-11. PubMed ID: 15368357
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 (IGF-1) induces the activation/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells.
Zheng WH; Quirion R
BMC Neurosci; 2006 Jun; 7():51. PubMed ID: 16792806
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.
Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Yang XM
Tumori; 2011; 97(6):762-70. PubMed ID: 22322844
[TBL] [Abstract][Full Text] [Related]
11. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
[TBL] [Abstract][Full Text] [Related]
12. Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1-Rap1 signaling: effects of silencing CREB gene expression on Akt activation.
Misra UK; Pizzo SV
J Biol Chem; 2005 Nov; 280(46):38276-89. PubMed ID: 16172130
[TBL] [Abstract][Full Text] [Related]
13. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.
Milani D; Zauli G; Rimondi E; Celeghini C; Marmiroli S; Narducci P; Capitani S; Secchiero P
J Neurochem; 2003 Jul; 86(1):126-35. PubMed ID: 12807432
[TBL] [Abstract][Full Text] [Related]
14. [Effects of combining tumor necrosis factor related apoptosis-inducing ligand with PI3-K-Akt inhibition on nasopharyngeal carcinoma cell].
Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Wang S; Yang XM
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Oct; 46(10):854-8. PubMed ID: 22321426
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphatidylinositol-3 kinase/Akt or mitogen-activated protein kinase signaling sensitizes endothelial cells to TNF-alpha cytotoxicity.
Zhang L; Himi T; Morita I; Murota S
Cell Death Differ; 2001 May; 8(5):528-36. PubMed ID: 11423913
[TBL] [Abstract][Full Text] [Related]
16. Loss of PTEN expression does not contribute to PDK-1 activity and PKC activation-loop phosphorylation in Jurkat leukaemic T cells.
Freeley M; Park J; Yang KJ; Wange RL; Volkov Y; Kelleher D; Long A
Cell Signal; 2007 Dec; 19(12):2444-57. PubMed ID: 17826953
[TBL] [Abstract][Full Text] [Related]
17. Hyperosmolality activates Akt and regulates apoptosis in renal tubular cells.
Terada Y; Inoshita S; Hanada S; Shimamura H; Kuwahara M; Ogawa W; Kasuga M; Sasaki S; Marumo F
Kidney Int; 2001 Aug; 60(2):553-67. PubMed ID: 11473638
[TBL] [Abstract][Full Text] [Related]
18. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
Kandasamy K; Srivastava RK
Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway.
Zauli G; Milani D; Mirandola P; Mazzoni M; Secchiero P; Miscia S; Capitani S
FASEB J; 2001 Feb; 15(2):483-91. PubMed ID: 11156964
[TBL] [Abstract][Full Text] [Related]
20. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
